207_Combined course Presentations

novel arm.

Trial

Patient No

Path Stage

Treatment arms

Median Age

Compliance to planned cycles

5 year DFS

MOSAIC (Andre 2004 updated 2015 NSABP C07 (Kuebler 2007) updated 2011

2246 II, III

LV5FU2

60

86.5%

67.5% vs 73.2%

FOLFOX4

61

74.7%

+5.7%

2407 II, III

FULV

59

Not stated

64.2% vs 69.4%

FLOX

59

Not stated

+5.2%

NO16968 (Haller 2011)

1886

III

FULV

61

83%

3-year DFS 70.9% vs 66.5%

XELOX

62

69%

+4.4%